ResMed (NYSE: RMD) closed down ~5.2% on Friday — a jarring reaction to a fiscal Q4 that, on paper, was a record. Which is exactly what makes the sell-off worth decoding.

This wasn't an earnings miss. Non-GAAP EPS came in at $2.95, ahead of the ~$2.89 the street wanted. The problem was the top line: revenue of ~$1.46B rose 9% to a record, but landed about $10M short of the ~$1.47B consensus. A hair's-width miss — but on a stock priced for steady beats, "in line" reads as a warning.

The bigger trigger was the outlook. Management guided FY2027 core revenue growth to just ~5–7%, a step down from the ~9% pace investors had gotten used to. Baked into that: a ~$75M revenue hit in FY27 from a field safety action on its Astral ventilators — a recall drag, not a demand problem, but a real number off the top. Gross margin also came in soft versus consensus on product-mix shift and higher logistics costs, even as full-year GAAP gross margin actually rose 170bps to 61.1%.

Layer on the overhang that's dogged RMD for two years: the GLP-1 fear. The bear case is that weight-loss drugs (Ozempic, Zepbound) shrink the sleep-apnea patient pool over time, so ResMed's core CPAP-and-mask franchise slowly loses future customers. Tellingly, masks & accessories revenue still grew 11% this quarter — the drugs aren't denting demand yet — but the market is trading the fear, not the print, and the stock sits near a 52-week low. A 10% dividend bump to $0.66/quarter didn't move it.

The ripple

The read-through runs straight to the drug side: every soft ResMed guide is quietly bullish for Eli Lilly (LLY) and Novo Nordisk (NVO), whose obesity drugs are the perceived structural threat. Watch apnea peer Inspire Medical (INSP) too — it sells a surgical implant alternative and trades on the same "how big is the apnea market in a GLP-1 world" narrative.

The one thing to watch: that ~5–7% FY27 growth guide is the number that settles this. If Q1 FY27 (reports late Oct/Nov) shows masks & accessories still compounding double-digits, the "GLP-1 kills ResMed" thesis loses steam and this de-rate looks overdone; if that line finally rolls over, there's more downside. Keep an eye on whether RMD holds its 52-week-low zone.

As of 8 Aug 2026, ~7:30 PM IST / 10:00 AM ET. Sources: Investing.com, MassDevice, TradingKey. For discussion and education only — not investment advice. Verify before acting.